These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7083457)

  • 1. A phase I trial of continuous infusion VP16-213 (etoposide).
    Aisner J; Van Echo DA; Whitacre M; Wiernik PH
    Cancer Chemother Pharmacol; 1982; 7(2-3):157-60. PubMed ID: 7083457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
    Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
    Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
    J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
    Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a new form of an oral administration of VP-16-213.
    Lau ME; Hansen HH; Nissen NI; Pedersen H
    Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
    Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J
    Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Stewart CF; Griffin JP
    Cancer Chemother Pharmacol; 1992; 31(2):161-6. PubMed ID: 1333371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical evaluation of doxifluridine.
    Hurteloup P; Armand JP; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
    Cancer Treat Rep; 1986 Jun; 70(6):731-7. PubMed ID: 2942245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
    Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
    Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of ICRF-187 by 48-hour continuous infusion.
    Koeller JM; Earhart RH; Davis HL
    Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.